Sartorius reported largely in-line Q4 19 numbers. Sales came in at €471.2m (+12.9%cc), driven by bioprocess solutions (+14.4%). Lab Products and Services (+8.7%) also ended the year on a high. EBITDA came in at €133.8m with the associated margin at 28.4%. Management expects FY 20 topline growth of 10-13%, EBITDA margin of 27.5% and capex at 10% of sales. Following the largely in-line results, we do not expect any significant changes to our estimates.
04 Feb 2020
Double digit status quo.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Double digit status quo.
Sartorius AG (0NIQ:LON) | 13,825 0 0.0% | Mkt Cap: 10,352m
- Published:
04 Feb 2020 -
Author:
Virendra Chauhan -
Pages:
3
Sartorius reported largely in-line Q4 19 numbers. Sales came in at €471.2m (+12.9%cc), driven by bioprocess solutions (+14.4%). Lab Products and Services (+8.7%) also ended the year on a high. EBITDA came in at €133.8m with the associated margin at 28.4%. Management expects FY 20 topline growth of 10-13%, EBITDA margin of 27.5% and capex at 10% of sales. Following the largely in-line results, we do not expect any significant changes to our estimates.